Phase II
Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced an oral presentation will be given at the 28th EADV Congress.
Auris Medical Holding Ltd., a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced that the first patient has been randomized in its “TRAVERS” Phase 2 trial of AM-125, the Company’s investigational drug for the treatment of acute vertigo.
A number of companies reported clinical trial data last week. Here’s a look.
Evotec SE announced that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough.
FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
Arcutis, Inc., a privately held immuno-dermatology drug development company addressing significant unmet needs in dermatology, announced positive top line results for its Phase 2b study evaluating ARQ-151 as a potential topical treatment for plaque psoriasis.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
PRESS RELEASES